SS-31 (50mg)

Description

What is SS-31 (Elamipretide)?

SS‑31 (also known as elamipretide, MTP‑131, or Bendavia) is a synthetic cell‑permeable tetrapeptide developed by Hazel Szeto at Weill Cornell and commercialized by Stealth BioTherapeutics. Its key innovation is selective concentration in the inner mitochondrial membrane where it binds cardiolipin and stabilizes mitochondrial cristae architecture, preserving electron transport chain function in conditions of oxidative stress.

Mechanism of Action

• Concentrates 1000‑5000 fold in the inner mitochondrial membrane (cationic/lipophilic balance)
• Binds cardiolipin, stabilizing the phospholipid scaffolding that organizes electron transport chain complexes
• Reduces mitochondrial ROS production and prevents opening of the mitochondrial permeability transition pore
• Preserves ATP synthesis under ischemia‑reperfusion and oxidative stress
• Unique target: does not scavenge ROS directly, but prevents pathologic ROS generation by stabilizing the site of production

Compound Properties

• Sequence: H‑D‑Arg‑2′,6’‑dimethyl‑Tyr‑Lys‑Phe‑NH₂
• Molecular formula: C₃₂H₄₉N₉O₅
• Molecular weight: ~639.80 g/mol
• CAS: 736992‑21‑5
• Form: Lyophilized powder
• Unit size: 50 mg / vial
• Source: Solid‑phase peptide synthesis; ≥98% purity by HPLC

Research‑Reference Dosing

Published research‑reference ranges from clinical trials of the commercial drug:

• Karaa et al., Neurology (2018) — MMPOWER trial: elamipretide in primary mitochondrial myopathy.
• Gibson et al., Lancet (2016) — EMBRACE trial: in ST‑elevation myocardial infarction reperfusion.
• Butler et al., JAMA Cardiology (2020): elamipretide in heart failure.
• Allen et al., Ophthalmology (2022): ReCLAIM‑2 trial in dry age‑related macular degeneration.

Research Findings

• Preserved ATP synthesis and reduced ROS in preclinical ischemia‑reperfusion models (Szeto 2014)
• Mixed clinical efficacy results across programs: signal in Barth syndrome and primary mitochondrial myopathy, negative in the pivotal MMPOWER‑3 endpoint
• Positive signal in ReCLAIM‑2 for geographic atrophy in dry AMD (Allen 2022)
• Heart failure trial endpoints were not met in pivotal studies

Known Side Effects Reported in Research/Trials

• Injection‑site reactions (most common AE across programs)
• Transient headache, nausea
• Generally well tolerated across multi‑year exposure cohorts
• Rare hypersensitivity

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.